Researchers have expressed concern regarding the use of bright light
therapy because the visible blue light wavelengths emitted by bright light therapy lamps
may cause retinal damage and could contribute to the development of age related blindness.
The patented light therapy technology used in a Lo-LIGHT therapy lamp eliminates the risk of retinal damage inhenent in the use of bright light or blue light therapy lamps. Lo-LIGHT lamps operate at normal indoor light intensity, and screen out the hazardous blue wavelengths of visible light that can damage the retina.
People using Bright Light or Blue Light therapy while taking photosensitizing medications
have an increased risk of eye damage. These medications, which sensitize the eye to damage by visible light,
include nonsteroidal anti-inflammatory drugs (NSAIDs), most antidepressants, some antibiotics, diuretics,
beta-blockers and other heart medications. Guidelines have been established recommending that Bright Light
therapy not be used with these photosensitizing medications.
A case report in the American Journal of Psychiatry described a person who combined the use of
Bright Light therapy and an antidepressant medication. After five days of using light therapy this patient suffered a
"marked reduction in visual acuity contrast sensitivity." Retinal examination found lesions in the retinas of both eyes.
In addition to those taking photosensitizing medications, those with an increased risk of vision loss
from bright or blue light therapy include people with a pre-existing ocular condition or a susceptibility for retinal
damage, such as those with diabetes. Older people also have a greater susceptibility to blue light induced retinal damage
because of the age-related decline in the ability of retinal defense mechanisms to repair oxidative damage that occurs
after age 40.
Exposure to blue visible light causes oxidative damage in the retina. Oxidative debris that results from this damage accumulates in the retina over a lifetime and is related to the development of age-related blindness. By age 75, more than one in every three people has Age-related Macular Degeneration (AMD), and this increases to over one half of people by age 85.
It is worth considering what Herbert Kern, the first person to use bright light therapy said in an article
in the journal Science marking the 25th aniversary of bright light therapy regarding his developing AMD. After explaining that
light therapy became less and less effective for him over the years as his eyesight faded, he said "Now I can hardly see, and
all hell has broken loose" "I have had periods of depression lasting over a year, and highs lasting as long."
See Part II - Light exposure and AMD
In North America, a no-risk rental program is available on some models. If the unit is purchased within 2 months from the time of rental, all rental payments are applied towards the purchase price. Order Now!
The Sunnex Biotechnologies Lo-LIGHT phototherapy lamp comes with a five year warranty. Details